Search

There are some distinctions between the two systems, but both are what is termed agentic; they operate in the background by calling out to separate tools. (Microsoft has taken a similar approach with its science assistant as well; OpenAI seems to be an exception in that it simply tuned an LLM for biology.) And, while there are differences between them that we’ll highlight, they are both focused on the same general issue: the utter profusion of scientific information. With the ease of online publishing, the number of journals has exploded, and with them the number of papers. It has gotten tough

For starters, it’s important to note that these successes come in one of the easier parts of drug development (not that any part of it can really be said to be easy). The AIs weren’t being asked to design entirely new molecules, and most drugs fail during the animal and clinical trials phase, rather than during testing in cell culture. That’s not to say repurposing existing drugs is nothing—we already have safety profiles and agency approvals for these molecules, and many are off-patent and therefore cheap. But we’re not at the point where AIs are solving hard problems. This sort of hypothesis